Sagimet Biosciences Inc/$SGMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sagimet Biosciences Inc
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Ticker
$SGMT
Sector
Primary listing
Employees
16
Headquarters
Website
SGMT Metrics
BasicAdvanced
$157M
-
-$1.58
3.40
-
Price and volume
Market cap
$157M
Beta
3.4
52-week high
$11.41
52-week low
$1.73
Average daily volume
431K
Financial strength
Current ratio
22.82
Quick ratio
22.177
Total debt to equity
0.07
Profitability
Management effectiveness
Return on assets (TTM)
-25.70%
Return on equity (TTM)
-38.20%
Valuation
Price to book
1.41
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-3.422
Free cash flow yield (TTM)
-29.22%
Free cash flow per share (TTM)
-1.411
Growth
Earnings per share change (TTM)
8.56%
3-year earnings per share growth (CAGR)
-78.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sagimet Biosciences Inc stock?
Sagimet Biosciences Inc (SGMT) has a market cap of $157M as of March 20, 2026.
What is the P/E ratio for Sagimet Biosciences Inc stock?
The price to earnings (P/E) ratio for Sagimet Biosciences Inc (SGMT) stock is 0 as of March 20, 2026.
Does Sagimet Biosciences Inc stock pay dividends?
No, Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Sagimet Biosciences Inc dividend payment date?
Sagimet Biosciences Inc (SGMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sagimet Biosciences Inc?
Sagimet Biosciences Inc (SGMT) has a beta rating of 3.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.